These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
731 related articles for article (PubMed ID: 23512881)
21. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Sookoian S; Pirola CJ Hepatology; 2011 Jun; 53(6):1883-94. PubMed ID: 21381068 [TBL] [Abstract][Full Text] [Related]
23. Adipocyte size is associated with NAFLD independent of obesity, fat distribution, and PNPLA3 genotype. Petäjä EM; Sevastianova K; Hakkarainen A; Orho-Melander M; Lundbom N; Yki-Järvinen H Obesity (Silver Spring); 2013 Jun; 21(6):1174-9. PubMed ID: 23913731 [TBL] [Abstract][Full Text] [Related]
24. APOC3rs2854116, PNPLA3rs738409, and TM6SF2rs58542926 polymorphisms might influence predisposition of NAFLD: A meta-analysis. Tong M; Wang F IUBMB Life; 2020 Aug; 72(8):1757-1764. PubMed ID: 32525256 [TBL] [Abstract][Full Text] [Related]
25. The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. Valenti L; Rametta R; Ruscica M; Dongiovanni P; Steffani L; Motta BM; Canavesi E; Fracanzani AL; Mozzi E; Roviaro G; Magni P; Fargion S BMC Gastroenterol; 2012 Aug; 12():111. PubMed ID: 22898488 [TBL] [Abstract][Full Text] [Related]
26. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Valenti L; Al-Serri A; Daly AK; Galmozzi E; Rametta R; Dongiovanni P; Nobili V; Mozzi E; Roviaro G; Vanni E; Bugianesi E; Maggioni M; Fracanzani AL; Fargion S; Day CP Hepatology; 2010 Apr; 51(4):1209-17. PubMed ID: 20373368 [TBL] [Abstract][Full Text] [Related]
27. Association of the I148M/PNPLA3 variant with elevated alanine transaminase levels in normal-weight and overweight/obese Mexican children. Larrieta-Carrasco E; León-Mimila P; Villarreal-Molina T; Villamil-Ramírez H; Romero-Hidalgo S; Jacobo-Albavera L; Gutiérrez-Vidal R; López-Contreras BE; Guillén-Pineda LE; Sánchez-Muñoz F; Bojalil R; Mejía-Domínguez AM; Méndez-Sánchez N; Domínguez-López A; Aguilar-Salinas CA; Canizales-Quinteros S Gene; 2013 May; 520(2):185-8. PubMed ID: 23510779 [TBL] [Abstract][Full Text] [Related]
28. Genetic polymorphisms associated with obesity and non-alcoholic fatty liver disease in Asian Indian adolescents. Jain V; Kumar A; Ahmad N; Jana M; Kalaivani M; Kumar B; Shastri S; Jain O; Kabra M J Pediatr Endocrinol Metab; 2019 Jul; 32(7):749-758. PubMed ID: 31216264 [TBL] [Abstract][Full Text] [Related]
29. Interactions of allelic variance of PNPLA3 with nongenetic factors in predicting nonalcoholic steatohepatitis and nonhepatic complications of severe obesity. Guichelaar MM; Gawrieh S; Olivier M; Viker K; Krishnan A; Sanderson S; Malinchoc M; Watt KD; Swain JM; Sarr M; Charlton MR Obesity (Silver Spring); 2013 Sep; 21(9):1935-41. PubMed ID: 23418085 [TBL] [Abstract][Full Text] [Related]
30. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Rotman Y; Koh C; Zmuda JM; Kleiner DE; Liang TJ; Hepatology; 2010 Sep; 52(3):894-903. PubMed ID: 20684021 [TBL] [Abstract][Full Text] [Related]
31. Lack of association between apolipoprotein C3 gene polymorphisms and risk of nonalcoholic fatty liver disease in a Chinese Han population. Niu TH; Jiang M; Xin YN; Jiang XJ; Lin ZH; Xuan SY World J Gastroenterol; 2014 Apr; 20(13):3655-62. PubMed ID: 24707151 [TBL] [Abstract][Full Text] [Related]
32. Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome. Stättermayer AF; Traussnigg S; Aigner E; Kienbacher C; Huber-Schönauer U; Steindl-Munda P; Stadlmayr A; Wrba F; Trauner M; Datz C; Ferenci P J Trace Elem Med Biol; 2017 Jan; 39():100-107. PubMed ID: 27908400 [TBL] [Abstract][Full Text] [Related]
34. PNPLA3, a genetic marker of progressive liver disease, still hiding its metabolic function? Dubuquoy C; Burnol AF; Moldes M Clin Res Hepatol Gastroenterol; 2013 Feb; 37(1):30-5. PubMed ID: 22884299 [TBL] [Abstract][Full Text] [Related]
35. Patatin-Like Phospholipase Domain-Containing 3 I148M Variant Is Associated with Liver Steatosis and Fat Distribution in Chronic Hepatitis B. Zampino R; Coppola N; Cirillo G; Boemio A; Grandone A; Stanzione M; Capoluongo N; Marrone A; Macera M; Sagnelli E; Adinolfi LE; del Giudice EM Dig Dis Sci; 2015 Oct; 60(10):3005-10. PubMed ID: 25986529 [TBL] [Abstract][Full Text] [Related]
36. Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis. Finkenstedt A; Auer C; Glodny B; Posch U; Steitzer H; Lanzer G; Pratschke J; Biebl M; Steurer M; Graziadei I; Vogel W; Zoller H Clin Gastroenterol Hepatol; 2013 Dec; 11(12):1667-72. PubMed ID: 23872669 [TBL] [Abstract][Full Text] [Related]
37. Genetic and clinical markers of elevated liver fat content in overweight and obese Hispanic children. Walker RW; Sinatra F; Hartiala J; Weigensberg M; Spruijt-Metz D; Alderete TL; Goran MI; Allayee H Obesity (Silver Spring); 2013 Dec; 21(12):E790-7. PubMed ID: 23804528 [TBL] [Abstract][Full Text] [Related]
38. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population. Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980 [TBL] [Abstract][Full Text] [Related]
39. The impact of PNPLA3 (rs738409 C>G) polymorphisms on liver histology and long-term clinical outcome in chronic hepatitis B patients. Brouwer WP; van der Meer AJ; Boonstra A; Pas SD; de Knegt RJ; de Man RA; Hansen BE; ten Kate FJ; Janssen HL Liver Int; 2015 Feb; 35(2):438-47. PubMed ID: 25284145 [TBL] [Abstract][Full Text] [Related]
40. I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease. Park JH; Cho B; Kwon H; Prilutsky D; Yun JM; Choi HC; Hwang KB; Lee IH; Kim JI; Kong SW Liver Int; 2015 Dec; 35(12):2537-46. PubMed ID: 26148225 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]